GlaxoSmithKline ( GSK ) also missed on sales in Q3 amid a 29% decline in healthcare product sales in China where it has faced bribery charges. After rallying on a slew corporate earnings and on hopes that the U.S. Federal Reserve will maintain its asset purchasing program in the wake of a disappointing jobs market report, stocks were poised to retreat Wednesday after China's central bank suggested it might tighten the cash flow to stem inflation risks. Especially for many metals, China has been the world's largest consumer and reduced spending could have ripple effects across the globe.